Dupilumab, a monoclonal antibody blocking interleukin-4 receptor-alpha (IL-4Ralpha), is an effective treatment for moderate to severe asthma and multiple allergic conditions. Mount Sinai researcher Thomas Marron, MD, PhD, believes it also has the potential to shift the battle against non-small cell lung cancer, in the realm of both treatment and prevention.